GlassScriptPhysician profile
Emmanuel Valery
NPI 1750334157
$3,041.96
in general payments reported to CMS, 2019-2025
26 companies · $1,051 in 2025
The $1,051 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $472 · 2020: $129 · 2021: $458 · 2022: $499 · 2023: $46.06 · 2024: $387 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,484.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $616.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $385.26 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Gilead Sciences, INC. | $276.31 | 2021-2025 | Livdelzi, Biktarvy |
| Abiomed | $274.96 | 2025 | |
| Exact Sciences Corporation | $200.30 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $162.06 | 2020-2022 | |
| Global Blood Therapeutics, INC. | $129.47 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $110.87 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $101.88 | 2024-2025 | Voquezna |
| Viiv Healthcare Company | $101.66 | 2020-2023 | Apretude |
| Lilly USA, LLC | $94.73 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $81.17 | 2024-2025 | Otezla, Repatha, Tepezza |
| Merck Sharp & Dohme LLC | $77.07 | 2019-2022 | |
| Novo Nordisk INC | $54.06 | 2020-2025 | Rybelsus, Ozempic |
| Acarix USA INC. | $52.64 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $51.49 | 2019 | |
| Abbott Laboratories | $48.62 | 2024-2025 | Freestyle Libre 3 |
| Ascensia Diabetes Care US INC. | $39.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $38.69 | 2019 | |
| Ardelyx, INC. | $34.99 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $28.43 | 2025 | |
| Eisai INC. | $19.96 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.09 | 2019 | |
| Pfizer INC. | $16.38 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.39 | 2019 | |
| Vanda Pharmaceuticals INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Valery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.